Kornimate/medical-research-clean huggingface dataset:
the effects of kinesio tape application with different verbal input given to with patients with rotator cuff tear

Conditions: Rotator Cuff Tear

Summary: the aim of the study to investigate the effectiveness kt application with different verbal inputs on pain, function and range of motion (rom) on patient with rotator cuff tear.

rotator cuff tears are most common of shoulder pain and functional limitations. kinesio tape (kt) are frequently used in the conservative treatment of shoulder pathology. even if some studies showed that kt is effective on pain, we think that it is due to positive thoughts of the patients about kt. the aim of the study to investigate the effectiveness kt application with different verbal inputs on pain, function and range of motion (rom) on patient with rotator cuff tear. 97 patients (group 1, n=32; group 2, n=33, group 3, n=32) were randomized into 3 groups according to verbal input given to patients about the effectiveness of kt; group 1 (it has been limited evidence of kt is effective), group 2 (it has been not known that kt is effective or not), group 3 (it has been known that kt has excellent result). the same standard kt was applied to 3 groups. the rest, night and pain in activity were assessed by visual analog pain scale (vas) before, after 30 min and 24 hours after kt application. rom assessed by goniometer and the function was evaluated by disabilities of the arm, shoulder and hand (dash) and the american shoulder and elbow surgery score (ases) before and 24 hours of kt application. minimal clinically important difference and effective were calculated for the assessments used in the study.

Eligibility criteria:
inclusion criteria: * patients were included in the study if they had a partial rotator cuff tear diagnosed on clinical grounds * no episodes of shoulder instability * no radiographic signs of fracture of the glenoid or the greater or lesser tuberosity mri evidence of cuff tear * duration of symptoms of at least 3 months, * inadequate response to nonoperative management (including nonsteroidal anti-inflammatory drugs, physical therapy, rest, and 1 local corticosteroid injection) positive empty can test indicating possible supraspinatus involvement * positive hawkins-kennedy test indicating possible external impingement, -subjective complaint of difficulty performing activities of daily living * 20 to 50 years of age. exclusion criteria: * patients were excluded from the study if they had inflammatory joint disease -rheumatologic disease osteoarthritis of humerus head * prior surgery on the affected shoulder * inability to complete questionnaires because of language problem or cognitive disorder * shoulder girdle fracture * glenohumeral dislocation/subluxation * acromioclavicular sprain * concomitant cervical spine symptoms * a history of shoulder surgery * patients who did not accept to participate * patients who did not come to the second evaluation.

Keywords: shoulder pain shoulder function
pilot e2 for hypogonadal women with cfbd

Conditions: Cystic Fibrosis Related Bone Disease

Summary: the study is a prospective, double blinded, placebo controlled, randomized study to evaluate the effects of daily oral estrogen supplements on bone health, sexual and reproductive health, quality of life and markers of inflammation and lung function when given to hypogonadal women with cystic fibrosis related bone disease (cfbd).

cystic fibrosis (cf) is the most common fatal heritable disease in non-hispanic whites; cf results in frequent lung infections, chronic inflammation and progressive lung failure. with advancements in medical care, patients with cf are living longer. the median survival of women with cf born and diagnosed in 2010 is projected to be 37 years. patients with cf are now living long enough to develop comorbidities like cystic fibrosis related bone disease (cfbd), hypogonadism manifesting as pubertal delay, premature ovarian insufficiency or hypothalamic hypogonadism. these comorbidities in women without cf can be improved by estrogen supplementation. it is well established that treating hypogonadal (low estrogen levels) women with estrogen can improve their bone health, slow the rate of bone loss and decrease bone turnover markers. supplemental estrogen given to hypogonadal women can improve sexual and reproductive health including reduction of perimenopausal symptoms and improvement in sexual function which can improve quality of life. there is very little research investigating the effects of estrogen treatment for hypogonadal women with cf. the purpose of this study is to test the hypothesis that daily oral estrogen supplements given to hypogonadal women with cfbd will improve their bone health, sexual and reproductive health, and quality of life and modify markers of inflammation and lung function.

Eligibility criteria:
inclusion criteria: * adult and adolescent female cf patients (age ≥ 18 years), * presenting to the cf clinic for routine follow up of cystic fibrosis, * hypogonadal women defined as e2 level \< 25, * dual energy x-ray absorptiometry (dexa) scan within 2 years of enrollment with t- or z-score \< -1, * able to tolerate oral medications. exclusion criteria: * inability to obtain or declined informed consent from the subject and/or legally authorized representative, * pregnancy, * too ill to participate in study based on investigator's or study team's opinion, * current use of systemic estrogen, * history of thromboembolic event within the previous 2 years, * history of migraines with aura, * hypercoagulability including previous diagnosis of factor v leiden or protein c or s deficiency, * current smoker, * history of diagnosis with breast or uterine cancer, * current significant liver disease with cholelithiasis or cirrhosis, * status post lung or liver transplantation, * current use of systemic steroids

Keywords: hypogonadism estrogen supplement
a study to learn more about using dienogest to treat endometriosis in chinese participants

Conditions: Endometriosis

Summary: endometriosis is a condition that affects women, usually during their reproductive years. in women with endometriosis, the tissue that lines the uterus starts to grow outside of the uterus. this can cause pain during their periods or during sex, and constant pain in the pelvis. endometriosis can decrease a woman's quality of life and requires long-term treatment to control the symptoms. for some women with endometriosis, symptoms can return after they stop treatment. or, they may not be able to tolerate the current long-term treatment options. in this study, researchers will find out more about the safety of long-term treatment with dienogest in a large number of chinese participants. this study will enroll patients from post-menarche to menopause with clinically or surgically diagnosed endometriosis. all of the participants will take dienogest based on their doctor's instructions. they will then visit their doctor's office 3 times over 6 months. during these visits, their doctors will ask them if they have any health problems and about their quality of life. their doctors will also do tests to measure the pain caused by their endometriosis and any other symptoms.


Eligibility criteria:
inclusion criteria: * signed informed consent. * post-menarcheal age through menopause. * have clinically or surgically diagnosed endometriosis according to routine clinical practice. * decision for the treatment with visanne was made as per physician's routine treatment practice. exclusion criteria: * patients participating in an investigational program with interventions outside of routine clinical practice. * any contraindication according to visanne chinese label
safety/efficacy study of ctap101 in chronic kidney disease subjects with secondary hyperparathyroidism (shpt)

Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism; Vitamin D Insufficiency

Summary: this study will investigate how the levels of a repeat dose of ctap101 changes in the body over time (pharmacokinetics, pk) and how ctap101 affects other mineral and hormonal balances (pharmacodynamics, pd) in patients with chronic kidney disease (ckd, vitamin d insufficiency and secondary hyperparathyroidism (shpt).


Eligibility criteria:
inclusion criteria: 1. urinary albumin excretion of ≤3000 μg of creatinine 2. stage 3 ckd 3. plasma ipth: \> 70 pg/ml and \< 500 pg/ml 4. serum ca: ≥ 8.4 mg/dl and \< 10.0 mg/dl 5. serum p: ≥ 2.0 mg/dl and \< 5.0 mg/dl 6. serum 25-hydroxyvitamin d: \> 10 ng/ml and \< 29 ng/ml. 7. discontinue vitamin d use for duration of study exclusion criteria: 1. history of kidney transplant or parathyroidectomy 2. spot urine calcium:creatinine ratio \> 0.2 3. current serious illness, such as malignancy, hiv, liver disease, cardiovascular event or hepatitis 4. currently on dialysis

Keywords: parathyroid diseases renal insufficiency kidney failure, chronic hyperparathyroidism, secondary vitamin d hyperparathyroidism kidney diseases kidney failure renal insufficiency, chronic
brain metastases in norway - a prospective cohort study

Conditions: Brain Metastases

Summary: the overall aim and primary outcome of this study will be a descriptive analysis of the current treatment practice of bm in norway. specifically, it may give answers to the following research questions: * what is the true incidence of bm in norway? * how are patients with bm treated at present? * do treatments differ between hospitals? * how do treatments impact quality of life of the patients? * which factors (treatment, tumor and host variables) can explain disease control, survival, symptom relief, and general functions? * how can bm staging be improved?


Eligibility criteria:
inclusion criteria: * verified cancer diagnosis of solid tumors (based on radiological, histological/cytological or operative evidence). * brain metastases verified by computer tomography (ct), contrast-enhanced magnetic resonance imaging (mri), or surgical biopsies * age ≥ 18 years * able to comply with study procedures * able to provide written informed consent after information in norwegian exclusion criteria: * primary brain tumors * primary hematological malignancies (lymphomas, leukemias) * previous diagnosis and/or treatment of bm * unable to produce written informed consent after information in norwegian

Keywords: treatment
a study of daclizumab (zenapax) in combination with mycophenolate mofetil (cellcept) and sirolimus in prevention of acute rejection in heart transplant participants

Conditions: Heart Transplantation

Summary: this study will evaluate the efficacy and safety of intravenous daclizumab in combination with oral mycophenolate mofetil and oral sirolimus in participants receiving a heart transplant, and at risk of impaired kidney function. the anticipated time on study treatment is 6 months, and the target sample size is 44 individuals.


Eligibility criteria:
inclusion criteria: * adult participants greater than 18 years of age * single organ (heart) transplant recipients * at risk for post-transplant renal dysfunction exclusion criteria: * previous organ transplant * previous treatment with mycophenolate mofetil, daclizumab or sirolimus * positive for human immunodeficiency virus (hiv) infection * history of malignancy within the last 5 years, except localized and treated skin cancer, treated and without evident relapse
epidemiological study to assess the symptoms and patterns of diagnosis and treatment of gerd

Conditions: GERD

Summary: to describe the frequency, type and severity of the symptoms in patients visiting the gi or internal physicians, with symptoms consistent with gastroesophageal reflux disease (gerd)


Eligibility criteria:
inclusion criteria: * patients from both sexes, aged 18 years or older * patients complaining of symptoms consistent with reflux disease exclusion criteria: * patients with gi cancer and those where the only reason for the visit is renewing the prescription are excluded

Keywords: gerd gis heartburn nis ppi
effects of gcp on prostate cancer.

Conditions: Prostate Cancer

Summary: genistein combined polysaccharide (gcp) is derived from adding soy powder to shiitake mushrooms. this concentrated mixture is currently being sold in japan and the united states and is thought to possibly contain properties that may be useful in treating certain types of cancer.


Eligibility criteria:
inclusion criteria: participants must be male and have a pathological diagnosis of prostate cancer. no treatment (surgery \[rrp\], radiation, or hormones) prior to study entry. the patient has decided, after consultation with his own doctor, to have no treatment intervention (surgery \[rrp\], radiation, or hormones) for the next six months. psa between 2.0 and 10.0 ng/ml. if psa is \>10.0, patient must have been on active surveillance for 12 months prior to study initiation. no known allergy to soy or soy products. the patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (otc supplements). - exclusion criteria: no pathological documentation of prostate cancer. allergy to soy or soy products prior history of treatment for prostate cancer. -

Keywords: prostate cancer prostate specific antigen c04.588.945.440.770
web-based psychological intervention to coronary artery heart disease patients

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to evaluate medical cost-effectiveness, reduce the psychological risk factors( including hostility, anxiety, depression, and perceived stress) in coronary artery disease (cad) patients and enhance the regulation of the autonomic nervous system (including respiration rate, heart rate, distal blood vessel pulse, and finger temperament) through web-based cognitive -behavioral group therapy.

cognitive-behavioral therapy (cbt) is effective in reducing the level of anger, hostility and depression present in coronary artery disease (cad) patients.in taiwan, weng et al. also confirmed the eight-week group cbt program not only diminished the emotion disturbances including anger, hostility and depression of cad, but also significantly prolonged the coagulation time, thus reducing the rate of thrombosis formation. even though the therapeutic effect of the cbt program was valid, this program is still not accessible for some patients in need because they are not aware of it, or they are restricted by time and transportation. internet-based therapeutic intervention can overcome the obstacles to access this program at any time and in any place. presently, structured cbt intervention is provided through the internet and used widely by patients with physical or psychological problems such as smoking, obesity, or headaches, but not by cad patients. therefore, the purpose of this research is to evaluate the effects to reduce the psychological risk factors of a web-based group cbt program in cad patients. follow-up assessments will be performed after 3 and 6-month durations. the investigators expect that, after an eight-week group intervention, there will be significant decrease of the psychological risk factors. moreover, the therapeutic effects can be maintained during the three- and six-month follow-up.evaluate in addition, web-based cognitive -behavioral group therapy will significantly reduce indirect medical costs (travel time and money).

Eligibility criteria:
inclusion: 1. coronary artery disease 2. regular medication exclusion: 1.psychiatric diseases
efficacy of iontophoresis-assisted afl-pdt in actinic keratosis

Conditions: Actinic Keratosis

Summary: iontophoresis is a transdermal drug-delivery technique that enhances the transport of ionic species across membranes and may have significant benefit for the treatment of actinic keratosis (ak) by ablative fractional laser-primed photodynamic therapy (afl-pdt).

photodynamic therapy (pdt) with methyl-aminolevulinate (mal) is effective in the treatment of actinic keratosis (ak). many strategies have been studied to improve the production of protoporphyrin ix (ppix), to improve efficacy of pdt. pre-treatment of the skin with fractional laser resurfacing is a novel alternative technique to improve the efficacy of pdt for ak. our previous studies showed that ablative fractional laser-primed pdt (afl-pdt) offered higher efficacy than conventional mal-pdt in the treatment of many diseases, such as ak, actinic cheilitis, bowen's disease and basal cell carcinoma.1-4 iontophoresis can be another method to improve efficacy of pdt. iontophoresis is a transdermal drug-delivery technique which uses a mild electric current to enhance the transport of ionic species across membranes. iontophoresis has been widely used to enhance drug delivery. mizutani k et al.5 reported 5 ak patients successfully treated with direct-current pulsed iontophoresis-assisted 5-aminolevulinic acid (ala)-pdt. boddé he et al.6 studied iontophoretic transport of ala quantitatively in vitro and demonstrated enhanced transport of ala by iontophoresis. until now, appropriate incubation time for afl-pdt has not been elucidated. in our previous study, we investigated the efficacy of afl-pdt with a short incubation time.7 although afl-pdt with a short incubation time (2 h) showed enhanced efficacy than conventional mal-pdt with the standard incubation time, standard afl-pdt with 3-h incubation time showed significantly higher efficacy than afl-pdt with a short incubation time. the aim of our study was to evaluate efficacy of iontophoresis in afl-pdt for ak treatment. consequently, we compared efficacy, recurrence rate, cosmetic outcome and safety between iontophoresis-assisted afl-pdt with 2-h incubation time and conventional afl-pdt with 2-h and 3-h incubation times.

Eligibility criteria:
inclusion criteria: * korean patients aged ≥ 18 years who had biopsy-confirmed ak lesions exclusion criteria: * lactating or pregnant women * patients with porphyria or a known allergy to any of the constituents of the mal cream and lidocaine * patients with systemic disease, history of malignant melanoma, tendency of melasma development or keloid formation, any ak treatment of the area in the previous 4 weeks, or any conditions associated with a risk of poor protocol compliance; and patients on immunosuppressive treatment * metal-containing device (cardiac pacemaker, orthopaedic implants, gynaecological devices) * cardiac arrhythmia * large skin erosion

Keywords: ablative fractional laser iontophoresis actinic keratosis photodynamic therapy
biliary interventions in critically ill patients with secondary sclerosing cholangitis (biscit)

Conditions: Secondary Sclerosing Cholangitis

Summary: this is a randomized, open-label, controlled, parallel group, multicenter clinical trial. patients with confirmed secondary sclerosing cholangitis (ssc-cip) will be randomized either in the intervention group undergoing scheduled invasive evaluation of the biliary tract or in the control group treated with non-interventional standard of care to demonstrate that programmed endoscopic therapy compared to a conservative strategy reduces the occurrence of treatment failures.


Eligibility criteria:
inclusion criteria: patients have to fulfill all of the following inclusion criteria to be eligible for participation in this study: 1. men, women\*, inter/divers, age ≥18 and ≤ 80 years (conscious or unconscious patients may be included) 2. signed written informed consent obtained by patient or legal representative in case of unconscious patient 3. willingness to comply with treatment and follow-up procedures 4. suspected ssc-cip = episode of critical illness and intensive care unit treatment \> 3 days within last 12 months 5. ssc-cip is confirmed by erc, (if the first erc is performed at baseline, the patient may be considered as screening failure if the diagnosis is not confirmed) 6. elevation of bilirubin ≥ 2.5 upper limit of normal (uln) at screening 7. elevation of alkaline phosphatase (ap) or gamma-glutamyl-transferase (ggt) \> 2.5 uln or elevation of both at screening 8. \*women without childbearing potential defined as follows: * at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or * hysterectomy or uterine agenesis or * ≥ 50 years and in postmenopausal state \> 1 year or * \ 1 year with serum follicle stimulating hormone (fsh) \> 40 iu/l and serum estrogen \< 30 ng/l or a negative estrogen test, both at screening or \*women of childbearing potential: * who are practicing sexual abstinence (periodic abstinence and withdrawal are not acceptable) or * who have sexual relationships with female partners only and/or with sterile male partners or * who are sexually active with fertile male partner, have a negative pregnancy test during screening and agree to use reliable methods of contraception (failure rate of \< 1% per year) from the time of screening until end of the clinical trial. exclusion criteria: 1. patient is too unstable to undergo erc 2. inclusion in any other intervention trial within the last 30 days 3. pregnancy or lactation period

Keywords: biliary intervention endoscopic therapy endoscopic retrograde cholangiography
the impact of immersive virtual reality training in thyroid surgery

Conditions: Virtual Reality Simulation; Thyroid Surgery

Summary: up to this date, there have been no reports on virtual reality (vr) training in thyroid surgery. the purpose of this study is to determine the impact of vr training in residents' education. investigators intend to include general surgery residents in the trial, subgrouped in a vr training group and another one with traditional learning, utilizing a technical textbook as a control. for the purpose of this study, a commercial available vr mask will be given for training in the vr group. randomization will be used to secure balance in the distribution of residents according to their experience. the task which will be examined include surgical steps from neck incision up to the placement of the c-ionm electrode and will be evaluated by a blinded febs certified endocrine surgeon in the operating theatre. training superiority will be assessed by the outcome measures of objective structured assessment of technical skills (osats) score, need for the main surgeon to intervene (nti), verbal answers and time to task completion. participants will complete questionnaires regarding satisfaction of the whole educational process.


Eligibility criteria:
inclusion criteria: * residents of the 2nd surgical department of aristotle university of thessaloniki * residents who have completed their 1st year of training programm. exclusion criteria: * disagreement of participants' randomisation * prolonged surgical time of completion * participant's experience beyond the included limits * participants who are completely incapable of using vr devices or have specific helath restrictions of using these * patients with complex thyroid disease such as recurrent disease, concominant primary hyperparathyroidism, lymph node disease or metastasis, graves disease and intrathoracic goiter

Keywords: endocrine surgery thyroid surgery virtual reality training